Product Name :
SNS-314
Description:
SNS-314 is a synthetic small molecule Aurora kinase (AK) inhibitor with potential antineoplastic activity. Aurora kinase inhibitor SNS-314 selectively binds to and inhibits AKs A and B, which may result in the inhibition of cellular division and proliferation in tumor cells that overexpress AKs. AKs are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis.
CAS:
1057249-41-8
Molecular Weight:
430.93
Formula:
C18H15ClN6OS2
Chemical Name:
N-(3-Chlorophenyl)-N’-[5-[2-(thieno[3, 2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea.
Smiles :
O=C(NC1=NC=C(CCNC2=NC=NC3C=CSC=32)S1)NC1=CC(Cl)=CC=C1
InChiKey:
FAYAUAZLLLJJGH-UHFFFAOYSA-N
InChi :
InChI=1S/C18H15ClN6OS2/c19-11-2-1-3-12(8-11)24-17(26)25-18-21-9-13(28-18)4-6-20-16-15-14(5-7-27-15)22-10-23-16/h1-3,5,7-10H,4,6H2,(H,20,22,23)(H2,21,24,25,26)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Pevonedistat} web|{Pevonedistat} NEDD8-activating Enzyme|{Pevonedistat} Biological Activity|{Pevonedistat} Data Sheet|{Pevonedistat} manufacturer|{Pevonedistat} Autophagy}
Shelf Life:
≥12 months if stored properly.{{Taletrectinib} medchemexpress|{Taletrectinib} Protein Tyrosine Kinase/RTK|{Taletrectinib} Biological Activity|{Taletrectinib} In Vitro|{Taletrectinib} supplier|{Taletrectinib} Autophagy}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
SNS-314 is a synthetic small molecule Aurora kinase (AK) inhibitor with potential antineoplastic activity. Aurora kinase inhibitor SNS-314 selectively binds to and inhibits AKs A and B, which may result in the inhibition of cellular division and proliferation in tumor cells that overexpress AKs. AKs are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis.|Product information|CAS Number: 1057249-41-8|Molecular Weight: 430.93|Formula: C18H15ClN6OS2|Synonym:|SNS314|SNS 314|SNS-314 free base|Related CAS Number:|1146618-41-8 (SNS-314 mesylate)|Chemical Name: N-(3-Chlorophenyl)-N’-[5-[2-(thieno[3, 2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea.|Smiles: O=C(NC1=NC=C(CCNC2=NC=NC3C=CSC=32)S1)NC1=CC(Cl)=CC=C1|InChiKey: FAYAUAZLLLJJGH-UHFFFAOYSA-N|InChi: InChI=1S/C18H15ClN6OS2/c19-11-2-1-3-12(8-11)24-17(26)25-18-21-9-13(28-18)4-6-20-16-15-14(5-7-27-15)22-10-23-16/h1-3,5,7-10H,4,6H2,(H,20,22,23)(H2,21,24,25,26)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO: 105 mg/mL(243.65 mM). Water: 6 mg/mL(13.92 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|In HCT116 colorectal carcinoma cell line, with intact or depleted p53 protein levels, SNS-314 Mesylate shows enhanced efficacy when administered sequentially with other standard chemotherapeutic agents and the most profound synergies are identified for agents that activate the spindle assembly checkpoint, e.PMID:24423657 g., docetaxel and vincristine. A recent study shows that SNS-314 Mesylate shows potent antiproliferative activity in HCT116 cells and inhibits soft agar colony formation.|In Vivo:|The sequential treatment with SNS-314 Mesylate followed by docetaxel 24 hours later produces a significant 72.5% tumor growth inhibition of HCT116 xenografts, while docetaxel and SNS-314 Mesylate as single agents produce no significant inhibition of HCT116 tumor growth. In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 Mesylate results a dose-dependent inhibition of histone H3 phosphorylation, indicating effective Aurora-B inhibition in vivo. In addition, HCT116 tumors from animals treated with SNS-314 Mesylate exhibits potent and sustained responses including reduction of phosphorylated histone H3 levels, increased caspase-3 and appearance of increased nuclear size.|References:|Arbitrario JP, et al. Cancer Chemother Pharmacol, 2010, 65(4), 707-717.VanderPorten EC, et al. Mol Cancer Ther, 2009, 8(4), 930-939.Oslob JD, et al. Bioorg Med Chem Lett, 2008, 18(17), 4880-4884.Products are for research use only. Not for human use.|
